Physician profile
Kerlie Estimable
NPI 1912294497
$912.03
in general payments reported to CMS, 2019-2025
17 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $114 · 2023: $108 · 2024: $103 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $196.42 | 2019-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.96 | 2019-2020 | |
| Abbott Laboratories | $108.26 | 2023 | Freestyle Libre 2 |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $51.27 | 2019 | |
| Pfizer INC. | $50.62 | 2019-2020 | |
| Novo Nordisk INC | $50.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.31 | 2019 | |
| Lilly USA, LLC | $36.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.35 | 2019 | |
| Merck Sharp & Dohme LLC | $26.62 | 2019 | |
| Allergan, INC. | $23.31 | 2019 | |
| Sanofi Pasteur INC. | $21.74 | 2019 | |
| Viiv Healthcare Company | $16.03 | 2024 | Apretude |
| Amgen INC. | $15.03 | 2025 | Repatha |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerlie Estimable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.